Molecules 2012, 17, 5187-5194; doi:10.3390/molecules17055187

Diterpenoid Alkaloids from the Chinese Traditional Herbal “Fuzi” and Their Cytotoxic Activity

Feng Gao *, Yuan-Yuan Li, Dan Wang, Xing Huang and Qian Liu

Department of Chinese Traditional Herbal, Agronomy College, Sichuan Agricultural University, No.221, Huming Road, Wenjiang Region, Chengdu 611130, China

* Author to whom correspondence should be addressed; E-Mail: gaofeng@sicau.edu.cn; Tel.: +86-28-8629-0970; Fax: +86-28-8629-0870.

Received: 21 March 2012; in revised form: 23 April 2012 / Accepted: 24 April 2012 / Published: 4 May 2012

Abstract: Ten diterpenoid alkaloids, including eight aconitine-type C_{19}-diterpenoid alkaloids and two hetisine-type C_{20}-diterpenoid alkaloids, were isolated from the secondary roots of Aconitum carmichaeli Debx., known as “Fuzi” in Chinese traditional herbal medicine. Their structures were established on the basis of their spectroscopic data and comparison with those of the literature. Among these alkaloids, chasmanine, oxonitine and 15-acetylsongoramine were isolated for the first time from this medicinal plant. The cytotoxic activity of the alkaloids were tested against several cell lines by the MTT method in which aconitine, hypaconitine, mesaconitine and oxonitine were found to strongly inhibit the growth of the HePG2 cell line, which showed that the existence and quantity of the ester groups have a significant influence on the cytotoxicity of the diterpenoid alkaloids.

Keywords: Fuzi; Aconitum carmichaeli Debx.; diterpenoid alkaloid; cytotoxicity

1. Introduction

The secondary roots of Aconitum carmichaeli Debx. (Ranunculaceae), a famous Chinese traditional herbal known as “Fuzi”, found mainly distributed in Jiangyou City of Sichuan Province in China, have long been used as an analgesic, anti-inflammatory and anti-tumor agent [1]. Diterpenoid alkaloids classed as belonging to the C_{18}-, C_{19}- and C_{20}-subtypes have been reported to be the main bioactive constituents of plants from the Aconitum genus [2]. Recently, the anti-tumor activity of these diterpenoid alkaloids with complex structures have attracted increasing interest [3,4].
Forty-seven alkaloids, including forty-three C19-diterpenoid alkaloids and four C20-diterpenoid alkaloids have been isolated from the *Aconitum carmichaeli* Debx [1,5]. In order to find more anti-tumor active substances, the secondary roots of *Aconitum carmichaeli* were phytochemically and pharmacologically investigated to obtain eight aconitine-type C19-diterpenoid alkaloids: aconitine (1), chasmanine (2), crassicauline A (3), oxonitine (4), deoxyaconitine (5), hypaconitine (6), mesaconitine (7), senbusine A (8), and two atisine-type C20-diterpenoid alkaloids, songoramine (9), 15-cetylsongoramine (10). The structures of isolated alkaloids were confirmed by the spectral analysis utilizing UV, IR, MS, and NMR, and comparison with the published data. Among them chasmanine (2), oxonitine (4) and 15-acetylsongoramine (10) were isolated for the first time from this medicinal plant. The cytotoxicity of isolated compounds was tested against several human cancer cell lines. Herein, we report the extraction, isolation, structural elucidation and cytotoxicity of diterpenoid alkaloids from the well-known Chinese traditional herbal medicine “Fuzi”.

2. Results and Discussion

The ten isolated compounds were identified as aconitine (1), chasmanine (2), crassicauline A (3), oxonitine (4), deoxyaconitine (5), hypaconitine (6), mesaconitine (7), senbusine A (8), and two atisine-type C20-diterpenoid alkaloids, songoramine (9) and 15-cetylsongoramine (10), by comparison of their 1H- and 13C-NMR spectroscopic data with those reported in the literature. Figure 1 shows the structures of the alkaloids.

![Figure 1. Structures of compounds 1–10.](image-url)

The cytotoxicity of the isolated ten alkaloids was evaluated against the human cancer cell lines HCT8, MCF7 and HePG2 and the results are shown in Table 1. Among these ten alkaloids, deoxyaconitine (5), oxonitine (4) and aconitine (1) exhibited the strongest cytotoxic activity against the HCT8, MCF7 and HePG2 cancer cell lines, respectively. Meanwhile, compounds 2, 8, 9 and 10 showed much lower activity than the other compounds.
Table 1. Cytotoxic data of compounds 1–10 from “Fuzi”.

| Compds | IC₅₀ (×10⁻⁸ M) HCT8 | IC₅₀ (×10⁻⁸ M) MCF7 | IC₅₀ (×10⁻⁸ M) HePG2 |
|--------|---------------------|---------------------|---------------------|
|        |                     |                     |                     |
| Taxol  | 4.49 ± 0.83         | 0.71 ± 0.25         | 0.12 ± 0.47         |
| 1      | 8.12 ± 0.23         | 2.45 ± 1.02         | 0.85 ± 0.06         |
| 2      | >1,000              | >1,000              | >1,000              |
| 3      | 16.45 ± 1.55        | 12.86 ± 3.52        | 2.36 ± 0.42         |
| 4      | 29.48 ± 3.12        | 3.13 ± 0.14         | 8.61 ± 1.31         |
| 5      | 5.14 ± 0.68         | 10.35 ± 1.24        | 9.21 ± 2.33         |
| 6      | 12.05 ± 0.76        | 6.46 ± 1.26         | 0.92 ± 0.06         |
| 7      | 13.16 ± 1.58        | 4.57 ± 0.29         | 1.45 ± 0.01         |
| 8      | >1,000              | >1,000              | >1,000              |
| 9      | >1,000              | >1,000              | >1,000              |
| 10     | >1,000              | >1,000              | 58.55 ± 9.17        |

HCT8: human colon cancer cell line; MCF7: human breast cancer cell line; HePG2: human liver cancer cell line.

Distinguishing differences in the anti-cancer bioactivity of the isolated compounds has been found in the MTT method. Analyzing the structures of the alkaloids and their anticancer data, we could conclude that: (1) the cytotoxic activities of C₁₉-diterpenoid alkaloids were universally stronger than those of C₂₀-diterpenoid alkaloids. For example, the only two C₂₀-diterpenoid alkaloids 9 and 10 display extremely weak potency; (2) the number of ester groups of alkaloids has an extraordinarily important influence on their cytotoxicity. Obviously, the cytotoxicities of the C₁₉-diterpenoid alkaloids containing two ester groups, such as aconitine (1), crassicauline A (3), oxonitine (4), deoxyaconitine (5), hypaconitine (6) and mesaconitine (7), were markedly stronger than those of chasmanine (2) and senbusine A (8) without the ester group substituent. With an additional acetyl group at C-15, 15-acetylsaongoramine (10) also was found to be more potent than saongoramine (9) against HePG2 cells. However, more pharmacological and biological experiments should be done to illustrate the interesting mechanism of action of how the ester groups influence the cytotoxic activity of diterpenoid alkaloids.

3. Experimental

3.1. General

¹H- and ¹³C-NMR spectra were taken on a Varian Unity INOVA 400/45 MHz NMR spectrometer in CDCl₃ with TMS as the internal standard. Silica gel H (Qingdao Sea Chemical Factory, Qingdao, China) was used as adsorbent for column chromatography. Spots on TLC (silica gel G, petroleum ether/acetone 1:1) were detected with modified Dragendorff’s reagent. Polyvinyl sulforic ion-exchange resin (H-form, Chemical Factory of Nankai University, Tianjin, China) was used in the extraction of the crude alkaloids.

3.2. Plant Material Collection and Identification

The secondary roots of *Aconitum carmichaeli* were collected from Jiangyou City of Sichuan Province, China in September 2011, and indentified as “Fuzi” from the 2010 Chinese Pharmacopoeia. A voucher specimen (No. 2011-9-16) was prepared from the entire plants of *Aconitum carmichaeli* and deposited in the herbarium of the Department of Chinese Traditional Herb, Agronomy College, Sichuan Agricultural University, China.
3.3. Extraction and Isolation

The powdered roots (1.8 kg) of *Aconitum carmichaeli* were percolated with 0.05 mol/L HCl (15 L). The aqueous acidic solution was basified with 10% aqueous NH₃·H₂O to pH 9–10 and then extracted with AcOEt (3 × 5 L). Removal of the solvent under reduced pressure afforded a total of 22.0 g of crude alkaloids as a yellowish amorphous powder. The total alkaloids (20 g) was chromatographed over SiO₂-column, eluting with a petroleum ether/acetone (10:1 → 1:2) gradient system to give Fractions A-G. Fr.A (1.28 g) was further subjected to column chromatography (CC, silica gel, cyclohexane/acetone 8:1 → 4:1) to give songoramine (28 mg) and chasmanine (46 mg). Fr.B (4.85 g) was also further subjected to CC (silica gel, chloroform/acetone 95:5 → 80:20) to yield aconitine (460 mg), crassicauline A (92 mg) and 15-acetylsongoramine (31 mg). Further normal phased CC purification of Fr.C (5.42 g) was accomplished by elution with a cyclohexane/acetone (6:1 → 2:1) to afford hypeaconitine (1.2 g), mesaconitine (840 mg), deoxyaconitine (49 mg) and senbusine A (18 mg). Fr.D (3.13 g) was chromatographed over SiO₂-column with CHCl₃/CH₃OH (9:1 → 8:1) to provide oxonitine (45 mg).

3.4. NMR Spectroscopic Data

*Aconitine* (1) was obtained as white needle-like crystals. \(^1\)H-NMR (400 MHz, CDCl₃): \(\delta_H\) 1.14 (3H, t, \(J = 7.2\) Hz, N-CH₂CH₃), 1.42 (3H, s, COCH₃), 3.27, 3.37, 3.38, 3.42 (each 3H, s, 4 × OCH₃), 5.02 (1H, d, \(J = 4.8\) Hz, H-14), 7.55–8.12 (5H, m, H-Bz). \(^{13}\)C-NMR (100 MHz, CDCl₃): \(\delta_C\) 83.4 (C-1), 33.6 (C-2), 71.5 (C-3), 43.2 (C-4), 46.8 (C-5), 83.4 (C-6), 44.7 (C-7), 92.1 (C-8), 44.2 (C-9), 40.9 (C-10), 50.0 (C-11), 35.8 (C-12), 74.1 (C-13), 78.9 (C-14), 78.9 (C-15), 90.0 (C-16), 61.1 (C-17), 78.8 (C-18), 48.9 (C-19), 47.0 (N-CH₂CH₃), 13.3 (N-CH₂CH₃), 174.2 (8-CO-CH₃), 21.4 (8-CO-CH₃), 55.9 (1-OCH₃), 59.1 (6-OCH₃), 57.9 (18-OCH₃), 166.1 (Ar-CO), 129.8 (C-1'), 129.6 (C-2', C-6'), 128.6 (C-3', C-5'), 133.3 (C-4'). NMR data were in accordance with those reported in the literature [6], which confirmed that the isolated compound 1 was aconitine.

*Chasmanine* (2) was obtained as a white amorphous power. \(^1\)H-NMR (400 MHz, CDCl₃): \(\delta_H\) 1.07 (3H, t, \(J = 7.2\) Hz, N-CH₂CH₃), 3.24, 3.31, 3.32, 3.34 (each 3H, s, 4 × OCH₃), 4.15 (1H, t, \(J = 4.8\) Hz, H-14β), 4.20 (1H, d, \(J = 6.8\) Hz, H-6β). \(^{13}\)C-NMR (100 MHz, CDCl₃): \(\delta_C\) 85.9 (C-1), 25.8 (C-2), 35.0 (C-3), 43.6 (C-4), 48.5 (C-5), 82.2 (C-6), 52.4 (C-7), 72.4 (C-8), 50.0 (C-9), 45.3 (C-10), 50.1 (C-11), 28.4 (C-12), 37.5 (C-13), 75.3 (C-14), 39.0 (C-15), 82.0 (C-16), 62.3 (C-17), 80.6 (C-18), 53.7 (C-19), 49.1 (N-CH₂CH₃), 13.6 (N-CH₂CH₃), 56.2 (1-OCH₃), 57.1 (6-OCH₃), 55.9 (16-OCH₃), 59.0 (18-OCH₃). NMR data were in accordance with those reported in the literature [7], which confirmed that the isolated compound 2 was chasmanine.

*Crassicauline A* (3) was obtained as white lamellar crystals. \(^1\)H-NMR (400 MHz, CDCl₃): \(\delta_H\) 7.97 (2H, d, \(J = 8.8\) Hz, H-2' and H-6'), 6.89 (2H, d, \(J = 8.8\)Hz, H-3' and H-5'), 4.85 (1H, d, \(J = 5.0\) Hz, H-14b), 3.94 (1H, d, \(J = 6.8\) Hz, H-6β), 3.84 (3H, s, Ar-OCH₃), 3.50, 3.25, 3.23, 3.12 (each 3H, s, 4 × OCH₃), 1.30 (3H, s, 8-OCOCH₃), 1.06 (3H, t, \(J = 7.2\) Hz, H-22). \(^{13}\)C-NMR (100 MHz, CDCl₃): \(\delta_C\) 83.8 (C-1), 26.4 (C-2), 34.9 (C-3), 39.4 (C-4), 49.0 (C-5), 83.1 (C-6), 45.1 (C-7), 85.7 (C-8), 49.6 (C-9), 41.1 (C-10), 50.4 (C-11), 36.0 (C-12), 75.0 (C-13), 78.7 (C-14), 39.5 (C-15), 84.9 (C-16), 62.1 (C-17), 80.5 (C-18),...
53.8 (C-19), 49.3 (N-CH₂CH₃), 13.6 (N-CH₂CH₃), 167.0 (8-OCOCH₃), 21.8 (8-OCOCH₃), 166.3 (14-CO-Ar), 122.8 (C-1'), 131.9 (C-2', C-6'), 113.9 (C-3', C-5'), 163.6 (C-4'), 59.2, 58.9, 57.9, 56.2, (4 × OCH₃), 55.6 (As-OCH₃). NMR data were in accordance with those reported in the literature [8], which confirmed that the isolated compound 3 was crassicauline A.

Oxonitine (4) was afforded as a white amorphous powder. ¹H-NMR (400 MHz, CDCl₃): δ: 1.33 (3H, s, 8-OAc), 3.13, 3.25, 3.32, 3.78 (each 3H, s, 4 × OCH₃), 4.87 (1H, d, J = 5.2 Hz, H-14β), 7.45–8.03 (5H, m, Ar-H), 8.10 (1H, s, N-COH). ¹³C-NMR (100 MHz, CDCl₃): δ: 82.8 (C-1), 34.2 (C-2), 69.9 (C-3), 42.2 (C-4), 49.2 (C-5), 79.8 (C-6), 50.9 (C-7), 90.3 (C-8), 43.1 (C-9), 40.5 (C-10), 49.7 (C-11), 33.6 (C-12), 74.2 (C-13), 78.8 (C-14), 78.5 (C-15), 90.0 (C-16), 57.9 (C-17), 74.8 (C-18), 38.7 (C-19), 163.1 (C-21), 55.6 (1-OCH₃), 57.6 (6-OCH₃), 61.1 (16-OCH₃), 59.3 (18-OCH₃), 172.3 (15-CO-CH₃), 21.4 (15-CO-CH₃), 166.2 (Ar-CO), 129.9 (C-1'), 129.6 (C-2', C-6'), 128.6 (C-3', C-5'), 133.3 (C-4'). The ¹H- and ¹³C-NMR spectral data were in accordance with those reported in the literature [9], which confirmed that the isolated compound 4 was oxonitine.

Deoxyaconitine (5) was obtained as white needle-like crystals. ¹H-NMR (400 MHz, CDCl₃): δ: 1.08 (3H, t, J = 7.1 Hz, N-CH₂CH₃), 3.69, 3.30, 3.28, 3.26 (each 3H, s, 4 × OCH₃), 8.02 (2H, d, J = 7.5 Hz, H-2', 6'). ¹³C-NMR (100 MHz, CDCl₃): δ: 85.3 (C-1), 26.4 (C-2), 35.1 (C-3), 39.1 (C-4), 48.9 (C-5), 83.5 (C-6), 49.3 (C-7), 82.1 (C-8), 47.0 (C-9), 42.1 (C-10), 48.8 (C-11), 37.1 (C-12), 74.9 (C-13), 78.5 (C-14), 80.5 (C-15), 91.1 (C-16), 61.7 (C-17), 80.0 (C-18), 53.6 (C-19), 50.4 (N-CH₂CH₃), 13.5 (N-CH₂CH₃), 56.3 (1-OCH₃), 59.1 (6-OCH₃), 61.5 (16-OCH₃), 57.9 (18-OCH₃), 166.3 (Ar-CO), 129.8 (C-1'), 129.8 (C-2', C-6'), 128.5 (C-3', C-5'), 133.2 (C-4'). NMR data were in accordance with those reported in the literature [10], which established that the isolated compound 5 was deoxyaconitine.

Hypaconitine (6) was afforded as white needle-like crystals. ¹H-NMR (400 MHz, CDCl₃): δ: 1.35 (3H, s, 8-OAc), 2.31 (3H, s, NCH₃), 3.70, 3.29, 3.25, 3.16 (each 3H, s, 4 × OCH₃), 4.89 (1H, d, J = 4.8 Hz, H-14β), 7.40–8.03 (5H, m, Ar-H). ¹³C-NMR (100 MHz, CDCl₃): δ: 83.4 (C-1), 36.1 (C-2), 71.2 (C-3), 43.7 (C-4), 46.9 (C-5), 82.6 (C-6), 44.5 (C-7), 92.1 (C-8), 43.9 (C-9), 41.1 (C-10), 50.2 (C-11), 34.2 (C-12), 74.3 (C-13), 79.1 (C-14), 90.3 (C-15), 62.3 (C-17), 76.5 (C-18), 49.6 (C-19), 56.4, 58.0, 59.3, 61.2 (4 × OCH₃), 42.6 (NCH₃), 172.5 (8-COCH₃), 21.6 (8-COCH₃), 166.2 (14-CO-Ar), 129.9 (C-1'), 129.8 (C-2', C-6'), 128.7 (C-3', C-5'), 133.3
(C-4'). ¹H- and ¹³C-NMR spectral data were in accordance with those reported in the literature [11], which confirmed that the obtained compound 7 was mesaconitine.

*Senbusine A* (8) was afforded as a white amorphous powder. ¹H-NMR (400 MHz, CDCl₃): δ_H 1.09 (3H, t, J = 7.2 Hz, N-CH₂CH₃), 3.28, 3.30 (each 3H, s, 2 × OCH₃), 4.19 (1H, t, J = 5.2 Hz, H-14β). ¹³C-NMR (100 MHz, CDCl₃): δ_C 72.1 (C-1), 29.3 (C-2), 29.6 (C-3), 37.9 (C-4), 48.3 (C-5), 72.7 (C-6), 55.3 (C-7), 76.4 (C-8), 45.6 (C-9), 40.4 (C-10), 49.8 (C-11), 29.7 (C-12), 44.1 (C-13), 75.6 (C-14), 42.3 (C-15), 82.1 (C-16), 63.6 (C-17), 80.3 (C-18), 57.0 (C-19), 48.2 (C-21), 13.0 (22), 56.3 (16-OCH₃), 59.1 (18-OCH₃). ¹H- and ¹³C-NMR spectral data matched those reported by the literature [12], which demonstrated that the obtained compound 8 was senbusine A.

*Songoramine* (9) was isolated as a white amorphous powder. ¹H-NMR (400 MHz, CDCl₃): δ_H 0.85 (3H, s, H₃-18), 1.04 (3H, t, J = 7.2 Hz, N-CH₂CH₃), 3.72 (1H, s, H-19β), 3.99 (1H, d, J = 1.6 Hz, H-17). ¹³C-NMR (100 MHz, CDCl₃): δ_C 67.6 (C-1), 24.2 (C-2), 29.6 (C-3), 37.7 (C-4), 48.4 (C-5), 23.9 (C-6), 45.9 (C-7), 50.1 (C-8), 31.3 (C-9), 51.6 (C-10), 31.1 (C-11), 208.6 (C-12), 53.0 (C-13), 37.3 (C-14), 76.9 (C-15), 149.9 (C-16), 111.9 (C-17), 18.8 (C-18), 92.8 (C-19), 66.1 (C-20), 48.4 (C-21), 14.4 (C-22). ¹H- and ¹³C-NMR spectral data were in accordance with those reported in the literature [13], which verified that the obtained compound 9 was songoramine.

*15-Acetylsongoramine* (10) was isolated as a white amorphous powder. ¹H-NMR (400 MHz, CDCl₃): δ_H 1.02 (3H, t, J = 7.2 Hz, N-CH₂CH₃), 0.84 (3H, s, 4-CH₃), 2.14 (3H, s, 15-OAc), 4.95, 5.26 (each 1H, s, H₂-17). ¹³C-NMR (100 MHz, CDCl₃): δ_C 67.6 (C-1), 29.6 (C-2), 24.2 (C-3), 37.8 (C-4), 48.0 (C-5), 23.8 (C-6), 46.0 (C-7), 49.2 (C-8), 32.7 (C-9), 51.5 (C-10), 31.5 (C-11), 208.1 (C-12), 53.4 (C-13), 37.2 (C-14), 76.0 (C-15), 144.2 (C-16), 113.0 (C-17), 18.8 (C-18), 92.7 (C-19), 65.9 (C-20), 48.2 (C-21), 14.1 (C-22), 170.5 (15-CO-CH₃), 21.4 (15-CO-CH₃). NMR spectral data were agreeable with those reported in the literature [14], which confirmed that the obtained compound 10 was 15-acetylsongoramine.

### 3.5. Determination of Cell Viability by MTT Assay

Cells were plated in the RPMI 1640 with 10% fetal calf serum media on 96-well plates in a 100 μL total volume at a density of 1 × 10⁴ cells/mL. Triplicate wells were treated with media and tested compounds. The plates were incubated at 37 °C in 5% CO₂ for 72 h. Cell viability was determined based on mitochondrial conversion of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT, Sigma) to formazan. The amount of MTT converted to formazan is a sign of the number of viable cells. Each well was supplemented with 50 μL of a 1 mg/mL solution of MTT in incomplete media. The plates were incubated in 37 °C, 5% CO₂ for another 4 h. The media was carefully removed from each well and 200 μL of DMSO was added. The plates were gently agitated until the color reaction was uniform and the OD₅₇₀ was determined using a microplate reader (Wellscan MK3, Labsystems Dragon). Microsoft® Excel 2000 was used for data analysis. Media-only treated cells served as the indicator of 100% cell viability. The 50% inhibitory concentration (IC₅₀) was defined as the concentration that reduced the absorbance of the untreated wells by 50% of the control in the MTT assay.
4. Conclusions

Ten diterpenoid alkaloids were isolated from the poisonous traditional Chinese herbal drug prepared from the secondary roots of *Aconitum carmichaeli* Debx., known as “Fuzi”. Among them three alkaloids, including chasmanine, oxonitine and 15-acetylsongoramine, were isolated from this medicinal plant for the first time. The cytotoxic activities of these alkaloids were also tested against several human cancer cell lines, which showed that the ester groups play a considerably important role in the anticancer potency of those diterpenoid alkaloids.

Acknowledgments

We are grateful to the National Natural Science Foundation of China (No. 81001383), the Doctoral Foundation of Ministry of Education of China (No. 20105103120009) and the grants from Education Department of Sichuan Province of China (No. 09ZB048). We also thank the State Key Laboratory of Biotherapy, Sichuan University, China, for the evaluation of biological activity.

References and Notes

1. Xiao, P.G.; Wang, F.P.; Gao, F.; Yan, L.P.; Chen, D.L.; Liu, Y. A pharmacophylogenetic study of *Aconitum* L. (Ranunculaceae) from China. *Acta Phytotaxon. Sin.* **2006**, *44*, 1–46.

2. Wang, F.P.; Chen, Q.H.; Liu, X.Y. Diterpenoid alkaloids. *Nat. Prod. Rep.* **2010**, *27*, 529–570.

3. Wada, K.; Hazawa, M.; Takahashi, K.; Mori, T.; Kawahara, N.; Kashiwakura, I. Inhibitory effects of diterpenoid alkaloids on the growth of A172 human malignant cells. *J. Nat. Prod.* **2007**, *70*, 1854–1858.

4. Wada, K.; Hazawa, M.; Takahashi, K.; Mori, T.; Kawahara, N.; Kashiwakura, I. Structure-activity relationships and the cytotoxic effects of novel diterpenoid alkaloid derivatives against A549 human lung carcinoma cells. *J. Nat. Med.* **2011**, *65*, 43–49.

5. Shen, Y.; Zuo, A.X.; Zhang, X.M.; Wang, H.L.; Chen, J.J. Two new C20-diterpenoid alkaloids from *Aconitum carmichaelii*. *Helv. Chim. Acta* **2011**, *94*, 122–126.

6. Borcsa, B.; Widowitz, U.; Csupor, D.; Forgo, P.; Bauer, R.; Hohmann, J. Semisynthesis and pharmacological investigation of lipo-alkaloids prepared from aconitine. *Fitoterapia* **2011**, *82*, 365–368.

7. Yang, J.; Liu, W.; Yang, X.; Zhao, J.; Liu, F.; Li, L. Diterpenoid alkaloids from *Aconitum handelianum*. *Zhongguo Zhong Yao Za Zhi* **2009**, *34*, 1927–1929.

8. Wang, F.P.; Fang, Q.C. Alkaloids from roots of *Aconitum crassicaule*. *Planta Med.* **1981**, *42*, 375–379.

9. Yunusov, M.S. Diterpenoid alkaloids. *Nat. Prod. Rep.* **1991**, *8*, 499–526.

10. Yunusov, M.S. Diterpenoid alkaloids. *Nat. Prod. Rep.* **1993**, *10*, 471–486.

11. Zhapova, T.; Modonava, L.D.; Semenov, A.A. Mesaconitine and hypaconitine from *Aconitum czekeanovskiy*. *Chem. Nat. Prod.* **1985**, *21*, 678–679.

12. Konno, C.; Shirasaka, M.; Hikino, H. Structure of senbusine A, B and C, diterpenie alkaloids of *Aconitum carmichaeli* roots from China. *J. Nat. Prod.* **1982**, *45*, 128–133.
13. Chen, H.C.; Wang, X.K.; Zhao, T.F.; Liao, X. Chemical constituents from *Aconitum carmichaeli*. *Nat. Prod. Res. Dev.* **2003**, *15*, 324–325.

14. Fan, Z.C.; Zhang, Z.Q. Molecular and crystal structure of 15-acetylsongorine and songoramine isolated from *Aconitum szechyanum* Gray. *Struct. Chem.* **2008**, *19*, 413–419.

*Sample Availability:* Samples of the compounds 1–3, 5–7, and 9 are available from the corresponding author.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).